Live Updates
Recent R&D and ongoing trials.
High-signal developments in stroke care — new trial results, important ongoing studies, and early signals worth watching. These are brief notes, not full analyses.
Educational summaries only
These notes are for awareness. Always go to primary sources and guidelines before changing practice.
Active & Upcoming
What to watch in 2026–2027.
TENSION — Tenecteplase in large-core ischemic stroke
Question
Can TNK safely extend thrombolysis benefit into large-core patients?
Status & Why It Matters
One of the most important ongoing trials for expanding reperfusion eligibility. Positive results would meaningfully change practice for a currently underserved population.
SELECT2 extended outcomes
Question
What do large-core thrombectomy patients look like at 1 year and beyond?
Status & Why It Matters
Will help answer whether the early benefit seen in SELECT2 holds up, and how we should counsel families.
MR CLEAN LATE real-world data
Question
How does late-window thrombectomy perform outside of trial centers?
Status & Why It Matters
Post-marketing European registry. Will show whether the benefits seen in trials translate to routine practice.
GLP-1 receptor agonists & stroke prevention
Question
Do the new weight-loss / diabetes drugs meaningfully reduce stroke risk?
Status & Why It Matters
Several large cardiovascular outcome trials with dedicated stroke endpoints are reading out. Could become an important secondary prevention tool.
This page is fed by our automated daily research digest (PubMed + ClinicalTrials.gov). Every week we also generate a **"This Week in Stroke"** summary for quick reading. All content is human-reviewed before publishing. For deeper analysis, see the full articles and the Trial Library.